ViiV Offers Entire HIV/AIDS Portfolio To Generic Firms In Low-Income Countries, No Royalties Attached
This article was originally published in The Pink Sheet Daily
With the problem of public access to medicines largely overcome, the new challenge is to get the more high-tech therapies to people with HIV/AIDS in the least developed countries, a spokeswoman said.
You may also be interested in...
ViiV Healthcare's Pipeline Sharing With Generic Makers "Meaningless" In Absence Of Technology - Cipla, IPA
MUMBAI - Cipla - India's biggest generic drug maker and among the largest manufacturers of generic anti-retroviral drugs in the world - expressed measured optimism to ViiV Healthcare's decision on offering access to the portfolio of its present and future pipeline of anti-retroviral medicines to 69 least developed and low-income countries without any royalty charges. Even so, a Cipla spokesman said he doubted if the steps announced on improving access to the medicines can be implemented
Merck's success with its HIV drug Isentress - the first and only integrase inhibitor on the market - and a recent shift in treatment guidelines that favor still greater use, are good signs for the emerging next-generation contenders in the class
ViiV Healthcare will market the two companies' combined portfolio of 10 HIV drugs while also taking over a 17-compound R&D operation.